Phase III Beckons For A Short-Course Seasonal Allergic Rhinitis Jab
A marketing approval for a seasonal allergic rhinitis vaccine from Allergy Therapeutics has moved nearer with positive top-line Phase II results that define the dose to be used in a Phase III study.
You may also be interested in...
A strong immunological response to the PQ Birch vaccine did not translate into any appreciable reduction in symptoms in the Phase III trial, leaving the UK firm perplexed, and its share price southwards.
Looking back at the second quarter, PharmaVitae analysts have selected 10 biopharma companies with market caps under $3bn they think are primed for acquisition – and the likely candidates for a buy-out.
The UK biotech’s potential revolutionary approach to allergies has failed to achieve its primary endpoint in a Phase III study, halting much of its research in the allergy area and casting a shadow over UK innovation.